BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37823514)

  • 1. SMAD4 loss predicts worse overall and distant metastasis-free survival in patients with resected pancreatic adenocarcinoma.
    Anstadt EJ; Carmona R; Berlin E; Yegya-Raman N; Venigalla S; Reddy V; Williams GR; Leibensperger MR; Wojcieszynski A; Baumann BC; Lee MK; Plastaras JP; Furth EE; Mell LK; Metz JM; Ben-Josef E
    Cancer; 2024 Feb; 130(3):476-484. PubMed ID: 37823514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
    McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
    Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients.
    Park JY; King J; Reber H; Joe Hines O; Mederos MA; Wang HL; Dawson D; Wainberg Z; Donahue T; Girgis M
    J Surg Oncol; 2021 Feb; 123(2):389-398. PubMed ID: 33146409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum Standard Uptake Value as a Clinical Biomarker for Detecting Loss of SMAD4 Expression and Early Systemic Tumor Recurrence in Resected Left-Sided Pancreatic Cancer.
    Kang CM; Hwang HK; Park J; Kim C; Cho SK; Yun M; Lee WJ
    Medicine (Baltimore); 2016 Apr; 95(17):e3452. PubMed ID: 27124039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression.
    Masugi Y; Takamatsu M; Tanaka M; Hara K; Inoue Y; Hamada T; Suzuki T; Arita J; Hirose Y; Kawaguchi Y; Nakai Y; Oba A; Sasahira N; Shimane G; Takeda T; Tateishi K; Uemura S; Fujishiro M; Hasegawa K; Kitago M; Takahashi Y; Ushiku T; Takeuchi K; Sakamoto M;
    J Pathol Clin Res; 2023 Sep; 9(5):339-353. PubMed ID: 37291757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases.
    Mizuno T; Cloyd JM; Vicente D; Omichi K; Chun YS; Kopetz SE; Maru D; Conrad C; Tzeng CD; Wei SH; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2018 May; 44(5):684-692. PubMed ID: 29551247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
    Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
    Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
    Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
    Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
    Hoyer K; Hablesreiter R; Inoue Y; Yoshida K; Briest F; Christen F; Kakiuchi N; Yoshizato T; Shiozawa Y; Shiraishi Y; Striefler JK; Bischoff S; Lohneis P; Putter H; Blau O; Keilholz U; Bullinger L; Pelzer U; Hummel M; Riess H; Ogawa S; Sinn M; Damm F
    EBioMedicine; 2021 Apr; 66():103327. PubMed ID: 33862582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.
    Kassem L; Deygas M; Fattet L; Lopez J; Goulvent T; Lavergne E; Chabaud S; Carrabin N; Chopin N; Bachelot T; Gillet G; Treilleux I; Rimokh R
    BMC Cancer; 2015 Jun; 15():453. PubMed ID: 26040677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Kozak MM; von Eyben R; Pai J; Vossler SR; Limaye M; Jayachandran P; Anderson EM; Shaffer JL; Longacre T; Pai RK; Koong AC; Chang DT
    J Clin Pathol; 2015 May; 68(5):341-5. PubMed ID: 25681512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Long-Term Survival in Pancreatic Ductal Adenocarcinoma after Pancreatectomy: TP53 and SMAD4 Mutation Scoring in Combination with CA19-9.
    Ono M; Ono Y; Nakamura T; Tsuchikawa T; Kuraya T; Kuwabara S; Nakanishi Y; Asano T; Matsui A; Tanaka K; Ebihara Y; Kurashima Y; Noji T; Murakami S; Shichinohe T; Mitsuhashi T; Omori Y; Furukawa T; Taniue K; Suzuki M; Sugitani A; Karasaki H; Mizukami Y; Hirano S
    Ann Surg Oncol; 2022 Aug; 29(8):5007-5019. PubMed ID: 35399143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.
    Pen SL; Shan YS; Hsiao CF; Liu TW; Chen JS; Ho CL; Chou WC; Hsieh RK; Chen LT; Ch'ang HJ
    Radiother Oncol; 2021 May; 158():146-154. PubMed ID: 33667587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
    Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
    Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a RNA-Seq Based Prognostic Signature in Lung Adenocarcinoma.
    Shukla S; Evans JR; Malik R; Feng FY; Dhanasekaran SM; Cao X; Chen G; Beer DG; Jiang H; Chinnaiyan AM
    J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27707839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.